Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
1.470
-0.140 (-8.70%)
At close: Mar 28, 2025, 4:00 PM
1.498
+0.028 (1.92%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Tango Therapeutics Stock Forecast
TNGX's stock price has decreased by -80.91% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Tango Therapeutics stock have an average target of 12.33, with a low estimate of 8.00 and a high estimate of 19. The average target predicts an increase of 738.78% from the current stock price of 1.47.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for Tango Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 5, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $16 → $8 | Strong Buy | Maintains | $16 → $8 | +444.22% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +784.35% | Nov 8, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $18 → $8 | Strong Buy | Maintains | $18 → $8 | +444.22% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +784.35% | Oct 28, 2024 |
Financial Forecast
Revenue This Year
29.58M
from 42.07M
Decreased by -29.68%
Revenue Next Year
25.34M
from 29.58M
Decreased by -14.34%
EPS This Year
-1.38
from -1.19
EPS Next Year
-1.41
from -1.38
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.6M | 44.2M | 47.6M | ||
| Avg | 29.6M | 25.3M | 31.5M | ||
| Low | 24.5M | n/a | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.5% | 49.3% | 87.6% | ||
| Avg | -29.7% | -14.3% | 24.2% | ||
| Low | -41.8% | - | -22.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.06 | -1.06 | -1.35 | ||
| Avg | -1.38 | -1.41 | -1.66 | ||
| Low | -1.53 | -1.65 | -2.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.